Relay: Lirafugratinib data show durable response across multiple FGFR2 tumors

Relay Therapeutics announced initial clinical data for RLY-4008 or lirafugratinib, in patients with FGFR2-altered solid tumors. The data demonstrate activity across several sub-groups, including patients with FGFR2-fusion tumors and patients with FGFR2-altered HR+/HER2- breast cancer. These data are being presented today at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.”These data provide important early evidence that RLY-4008, or lirafugratinib, has the potential to help both patients with FGFR2-fusion cholangiocarcinoma as previously reported, as well as those with multiple other types of FGFR2-altered tumors,” said Don Bergstrom, M.D., Ph.D., President of R&D at Relay Therapeutics. “We are excited by the potential for lirafugratinib to help many more patients and are focused on advancing this opportunity as well as our PI3Ka programs, with the initiation of a RLY-2608 triplet combination trial this year.”…The company will continue to prioritize and expand further PI3Ka mutant selective development, including:RLY-2608: continue ongoing ReDiscover trial with focus on RLY-2608 + fulvestrant cohorts…With the decision to pause CCA commercial readiness and RLY-2139 development, Relay Therapeutics expects its cash, cash equivalents and investments will be sufficient to fund its current operating plan into the second half of 2026.